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Background. We describe the performance of GeneXpert MTB/RIF (Xpert) for diagnosing tuberculosis (TB) among sympto-
matic household contacts (HHCs) of rifampicin-resistant and drug-sensitive index cases.
Methods. We conducted a cross-sectional study among HHCs of recently diagnosed (<2 weeks) smear-positive and Xpert-
positive index cases in the Bojanala District, South Africa. The HHCs were screened for TB symptoms; persons with ≥1 TB symptom 
provided 1 sputum for smear microscopy, Xpert, and mycobacterial growth indicator tube (MGIT) culture. Diagnostic test perfor-
mance of Xpert was determined using MGIT as the reference standard.
Results. From August 2013 to July 2015, 619 HHCs from 216 index cases were enrolled: 60.6% were female, median age was 
22 years (interquartile range, 9–40), and 126 (20.4%) self-reported/tested human immunodeficiency virus positive. A total of 54.3% 
(336 of 619) of contacts had ≥1 TB symptom (cough, fever, night sweats, weight loss), 297 of 336 (88.4%) of which provided a 
sputum; 289 (97.3%) had complete testing and 271 were included in the analysis. In total, 42 (6.8%) of 619 HHCs had microbiologi-
cally confirmed TB. The MGIT identified 33 HHCs as positive for Mycobacterium tuberculosis; of these, 7 were positive on Xpert re-
sulting in a sensitivity of 21.2% (95% confidence interval [CI], 9.0–38.9), specificity of 98.3% (95% CI, 95.6–99.5), positive predictive 
value of 63.6% (95% CI, 30.8–89.1), and negative predictive value of 90.0 (95% CI, 85.7–93.4).
Conclusions. Among symptomatic HHCs investigated for TB, Xpert performed suboptimally compared with MGIT culture. 
The poor performance of Xpert for diagnosing TB suggests that a more sensitive test, such a Xpert Ultra or culture, may be needed 
to improve yield of contact investigation, where feasible.
Keywords.  GeneXpert MTB/RIF; household contacts; mycobacterial culture; TB disease.
South Africa remains one of the highest tuberculosis (TB) burden 
countries in the world. The 2019 report from the World Health 
Organization (WHO) estimates the TB incidence is 520 per 
100 000 population, suggesting that despite ongoing efforts, more 
directed strategies are required to curb the epidemic [1]. Recent 
initiatives such as “Find. Treat. All.” recognize that scaling up the 
implementation of effective interventions by high-burden coun-
tries are required for us to realize the End TB strategy.
Active case-finding delivered through household contact 
tracing (HHCT) is a well established method for detecting and 
preventing TB [2–4] and has been recommended since 2012 [5, 
6]. However, the adoption of HHCT has been mixed, likely due 
to the effort and cost required to conduct screening and var-
iable TB disease yield among contacts [7–12]. Sputum-smear 
microscopy has been the mainstay of TB diagnosis in many 
resource-limited settings [13]; however, its inherently lower 
sensitivity compared with newer TB diagnostics undermines 
the value of HHCT when it is used. The introduction of the 
GeneXpert MTB/RIF (Xpert) assay, an automated molecular 
test for Mycobacterium tuberculosis (MTB) [14], has demon-
strated significant improvements over existing TB diagnostics 
resulting in the WHO recommending its use as a first-line test 
for TB diagnosis [5, 6].
South Africa adopted Xpert as the initial diagnostic test for 
investigating persons with symptoms suggestive of TB in 2011 
[15], primarily because of its shorter turnaround time when 
compared with mycobacterial culture and its ability to con-
currently diagnose rifampicin-resistant TB (RR-TB). However, 
when bacterial burden within expectorated respiratory speci-
mens is lower than the detection limit, Xpert may not be effective 
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in diagnosing TB compared with mycobacterial culture [16]. 
A 2015 systematic review of Xpert for diagnosing pulmonary 
TB in children found that Xpert offers better sensitivity com-
pared with smear microscopy; however, its sensitivity remains 
suboptimum compared with mycobacterial culture [17]. In ad-
dition, in the Gambia, among symptomatic household contacts 
(HHCs) <15  years old with induced sputum samples, Xpert 
returned a sensitivity of 42.9% (95% confidence interval [CI], 
17.7–71.1) compared with mycobacterial culture [18]. In con-
trast, a pilot study from Tanzania evaluated the performance of 
Xpert for identifying undiagnosed TB among 5 culture-positive 
HHCs reported sensitivities of 60% (95% CI, 14.7–94.7) and 
100% (95% CI, 47.8–100.0) for smear-microscopy and Xpert, 
respectively [19].
With a strong emphasis on identifying “missing TB patients” 
and scale-up of preventive therapy, particularly among HHCs, 
as well as the global adoption of Xpert for diagnosing TB in 
adults and children [20], it is imperative that we understand its 
performance for diagnosing TB among HHCs. We aimed to de-
termine the yield and performance of Xpert in diagnosing TB 
compared with mycobacterial culture among symptomatics 
HHCs within a TB contact tracing program.
METHODS
Setting
This study was nested within The CDC-Aurum contact tracing 
study, a multicountry prospective cohort study (South Africa, 
Kenya, and China) with the primary aim of comparing the yield 
of active TB disease among HHCs of index patients with RR-TB 
to those with drug-susceptible TB (DS-TB).
Study Procedures
Index patients diagnosed with RR-TB or DS-TB were identified 
through routine case detection within the Bojanala District of 
the Northwest Province. According to the 2015/2016 District 
Health Barometer, the incidence of TB in Bojanala district was 
estimated at 419 per 100  000 population, with an estimated 
human immunodeficiency virus (HIV) coinfection rate among 
TB patients of 66.6% [21].
Pulmonary index patients were eligible if recently diagnosed 
(≤2 weeks), Xpert or MTB culture-positive, or smear-positive. 
Index patients and their HHCs provided written informed con-
sent before study participation; an additional consent form was 
completed for children <18 years old by their respective guard-
ians. The HHCs ≥5 years old were screened using a symptom 
screening questionnaire; any HHC reporting ≥1 symptom 
(cough ≥24 hours, night sweats, fever, or unintentional weight 
loss) was investigated. One spot sputum collected was sent to 
a single reference laboratory for quality-assured smear micros-
copy, Xpert, and mycobacterial growth indicator tube (MGIT) 
testing. The HHCs <5  years old were referred to their local 
health facility for further TB investigation and preventative 
therapy.
Each sputum specimen was decontaminated using NaOH-
NALC-sodium citrate solution to a final (NaOH) of 1%. After 
centrifugation, the pellet was suspended in approximately 
1.5–2 mL phosphate buffer pH 6.8. The sediment was split to 
perform all TB testing; an aliquot was taken first for MGIT 
testing as previously described [22] to prevent contamination 
followed by Xpert and then smear microscopy. A  genotype 
MTBC test (HAIN Lifescience, Germany) was performed on 
all culture-positive samples to differentiate between MTB and 
non-TB mycobacteria. Individuals with positive TB test results 
were recontacted and provided with a referral letter to initiate 
treatment.
Human immunodeficiency virus counseling and testing was 
offered to all HHCs within the households if they reported an 
unknown or negative HIV status at the time of the visit. Any 
individual testing positive for HIV was referred to their local 
health facility for care.
Definitions and Statistical Analysis
A culture was positive if MTB was detected after being identi-
fied to species level; a negative culture was defined as the ab-
sence of MTB growth after 42 days. Time to culture positivity 
(TTCP), defined as the number of days it took for a positive cul-
ture result on the MGIT culture system, was used as a measure 
of mycobacterial burden.
Descriptive statistics were used to summarize demographic 
and socioeconomic characteristics of HHCs included in the 
analysis. Overall TB yield was defined as the proportion of 
TB cases diagnosed as positive on either MGIT culture or 
Xpert MTB/RIF or smear microscopy among those evaluated. 
Diagnostic yield was defined as the (no. of positive tests/total no. 
of tests performed) × 100. All CIs for proportions were exact. 
Comparison of proportions calculated from different sam-
ples (eg, sensitivity of Xpert among smear-positive vs smear-
negative) were done using Fisher’s exact test. Comparison of 
proportions calculated from the same sample (for example, 
sensitivity of Xpert compared with sensitivity of smear micros-
copy) was done using McNemar’s test.
Xpert sensitivity, specificity, positive predictive value (PPV), 
and negative predicative value (NPV) were calculated using 
MGIT culture as the reference standard. Xpert assay cycle 
threshold values (CT), which is defined as the number of pol-
ymerase chain reaction cycles completed after which each of 
the 5 probes is considered positive, was also documented. This 
provided a semiquantitative measure of bacillary burden in 
sputum, reported as high (<16 cycles), medium (16–22 cycles), 
low (23–28 cycles), and very low (>28 cycles) [23]. We excluded 
specimens that were culture-contaminated from the diag-
nostic performance analyses. Data was analyzed using Stata 13 








niversity user on 07 June 2021
GeneXpert Performance in TB Contacts • ofid • 3
HHC was determined by combining the self-reported status 
with additional testing results obtained through testing that was 
conducted within the households.
Patient Consent Statement
All study participants provided written consent, and the study 
was approved by the ethics committees of the University of 
the Witwatersrand Human Research Ethics Committee, US 
Centers for Disease Control and Prevention, and the research 
committee of the North West Province, South Africa.
RESULTS
Index Patient Characteristics
From August 2013 to July 2015, we enrolled 216 index TB cases: 
73 with RR-TB and 145 with DS-TB (Table 1). The median age 
was 36 years (interquartile range [IQR], 33–41) for RR-TB pa-
tients and 37 years (IQR, 35–40) for DS-TB patients. The me-
dian number of HHCs per index patient was 3 (IQR, 1–4) for 
both RR-TB and DS-TB patients.
Household Contact Characteristics
There were 619 HHCs included from the 216 index patients. 
Median age was 22  years (IQR, 9–40) (Table 2) and females 
comprised 60.6% of enrolled HHCs. Previous history of TB 
was reported among 42 (6.8%) HHCs. There were 336 (54.3%) 
HHCs who presented with at least 1 TB symptom; a cough ≥24 
hours was the most common symptom, which was reported by 
98.5% of symptomatic contacts. A sputum sample was collected 
from 297 (88.4%) symptomatic contacts representing 47.8% of 
all HHCs; 289 (97.3%) had complete results for all 3 diagnostic 
tests. One hundred seventeen (18.9%) contacts self-reported 
being HIV positive, and 291 (47.0%) contacts had an unknown 
or negative HIV status at enrollment; of these, 45 (15.5%) were 
tested for HIV, and 9 of these were HIV positive. The overall 
HIV prevalence was 20.4%.
Comparison of Diagnostic Performance
Mycobacterial Growth Indicator Tube Culture and Smear 
Microscopy Testing
Figure 1 shows the results of Xpert and MGIT tests for the 289 
specimens. The MGIT testing identified 33 (11.4%) patients 
as positive for MTB, 8 (2.8%) were non-TB mycobacteria, 18 
(6.2%) were contaminated, and 230 (79.6%) were negative for 
any growth. The median TTCP among culture-positive con-
tacts was 12 days (IQR, 9–22) with a range of 2–37 days (Figure 
2). Among samples that were both MGIT culture- and Xpert-
positive, the median TTCP was 6  days (IQR, 5–10), whereas 
among samples that were MGIT culture-positive and Xpert 
negative, the median TTCP was 18 days (IQR, 10–26).
Smear microscopy was performed on 289 samples, but 271 
were included in the analysis; 5 were smear-positive and 266 
were smear negative. Sensitivity of smear microscopy for detec-
tion of MTB, using MGIT culture as reference standard, was 3 
of 33 (9.0%; 95% CI, 1.9–24.3) versus Xpert sensitivity of 21.2% 
overall (P < .001) (Table 3).
Table 1. Characteristics of Index RR-TB and DS-TB Patients
Characteristic MDR-TB (n = 73) DS-TB (n = 145)
Gender, n (%)   
Male 39 (53.4)  78 (53.8)
Female 34 (46.6)  67 (46.2)
Age, n (%)   
18–29 17 (23.3) 30 (20.7)
30–39 26 (35.6) 52 (35.9)
40–49 21 (28.8) 47 (32.4)
≥50 9 (12.3) 16 (11.0)
Median (IQR) 36 (30–45) 37 (30–45)
Number of HHCs, n (%)   
1 21 (28.8) 38 (26.2)
2 15 (20.6) 26 (17.9)
3 9 (12.3) 28 (19.3)
4 13 (17.8) 20 (13.8)
≥5 15 (20.5) 33 (22.8)
HIV Status, n (%)   
Positive 62 (84.9) 100 (69.9)
Negative 11 (15.1) 43 (30.1)
Abbreviations: DS, drug susceptible; HHC, household contact; HIV, human immunodefi-
ciency virus; IQR, interquartile range; MDR, multidrug resistant; TB, tuberculosis; RR, ri-
fampicin resistant.
Table 2. Characteristics of HHCs and Culture-Positive TB Cases
Characteristic
All HHCs  
(N = 619)
Culture-Positive TB 
Cases (N = 33)
Gender, n (%)   
Male 244 (39.4) 16 (48.5)
Female 375 (60.6) 17 (51.5)
Age, n (%)   
<18 263 (42.5) 12 (36.4)
18–29 123 (19.9) 7 (21.1)
30–39 74 (12.0) 4 (12.1)
40–49 59 (9.5) 6 (18.2)
≥50 100 (16.1) 4 (12.2)
Median (interquartile range) 22 (9–40) 27 (14–42)
TB Symptoms, n (%)   
Cough ≥24 hours 331 (53.5) 33 (100.0)
Fever 20 (3.2) 3 (9.1)
Night sweats 18 (2.9) 2 (6.1)
Unintentional weight loss 30 (4.9) 5 (15.2)
≥1 TB symptoms 336 (54.3) 33 (100.0)
≥2 TB symptoms 41 (6.6) 5 (15.2)
≥3 TB symptoms 13 (2.1) 2 (6.1)
HIV Status, n (%)   
Positive  126 (20.4) 10 (30.3)
Negative  493 (79.6) 23 (69.7)
Previous history of TB, n (%)   
Yes 42 (6.8) 6 (18.2)
No 577 (93.2) 27 (81.8)
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Xpert Testing
Xpert testing identified 16 (5.5%) patients as positive for MTB. The 
Xpert quantitation results for the 16 sputa in which MTB was de-
tected were “high” for 4 (25.0%), “medium” for 1 (6.3%), “low” for 
6 (37.5%), and “very low” for 5 (31.2%). The mean CT value among 
Xpert-positive contacts was 24.2 (95% CI, 20.8–27.8), the median 
was 24.9 (IQR, 17.3–30.6), and the range was 13.5–33.1. Four of 
the 16 Xpert-positive patients tested negative on MGIT culture; 2 
were smear-positive (1+) and 2 were smear-negative.
Xpert performance characteristics, stratified by smear and 
HIV status, using MGIT culture as the reference standard are 
shown in Table 3. Overall, 271 (93.8%) sputa had an interpret-
able result for MGIT and Xpert; we excluded 18 specimens from 
this analysis that were contaminated in MGIT (5 Xpert-positive 
and 13 Xpert-negative). Xpert sensitivity was 21.2% (95% CI, 
9.0–38.9), specificity was 98.3% (95% CI, 95.6–99.5), PPV was 
63.6% (95% CI, 30.8–89.1), and NPV was 90.0 (95% CI, 85.7–
93.4). Xpert sensitivity was higher for smear-positive specimens 
than for smear-negative specimens; 100% (3 of 3)  for smear-
positive vs 12.9% (4 of 30) for smear-negatives, P = .06.
Xpert sensitivity was higher for patients who were HIV-
positive than for HIV-negative patients, although not statisti-
cally significant: 40.0% (4 of 10) for HIV-positive vs 13.0% (3 of 
23) for HIV-negatives, P = .21. Similarly, there was no statistical 
evidence for a difference by HIV status in Xpert PPV (66.7% in 
HIV-positive vs 60.0% in HIV-negative; P = 1.0). Xpert spec-
ificity was 98.9% for HIV-negative vs 96.1% for HIV-positive 
(P = .9) or NPV (90.2% for HIV-negative vs 89.3% for HIV-
positive; P = 1.0).
Among specimens with MTB detected by Xpert, rifampicin 
resistance was detected in 2 of 16 (12.5%). The 2 specimens 
that were rifampicin resistant on Xpert were contaminated on 
MGIT culture; therefore, phenotypic drug-susceptibility testing 
could not be performed.
Among the 42 TB cases identified through either MGIT cul-
ture, Xpert, or smear microscopy, 81% (34 of 42) were started on 
TB treatment; this was reported through patient record review 
at the referring health facility. Among TB cases diagnosed on 
culture (n = 33), 26 (79%) were successfully started on TB treat-
ment, whereas among TB cases diagnosed on Xpert (n = 16), 12 
(75%) were successfully started on TB treatment.
DISCUSSION
In evaluating Xpert diagnostic performance among HHCs, we 
found that it performed poorly in comparison to mycobacterial 
culture, diagnosing only 21.2% of all culture-confirmed cases, 
although still better than smear microscopy. Xpert diagnostic 
HH contacts consented
(N = 619)
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performance was possibly influenced by low bacillary burden, 
an expected consequence of active case finding that has impor-
tant programmatic implications for TB elimination efforts. Our 
study, conducted among HHCs of RR-TB and DS-TB index 
patients, found a high microbiologically confirmed TB yield 
of 6.8% when testing a single spot sputum using either culture 
or Xpert.
Tuberculosis yield identified among HHCs in our study is 
consistent with other studies conducted in South Africa [11, 12], 
but double the 3.1% estimate from a meta-analysis conducted 
by Fox et al [24] in 2013. In addition, we demonstrated a higher 
microbiologically confirmed yield than a recent multicountry 
study conducted among contacts of multidrug-resistant TB 
index patients that reported a TB yield of 2% among bacteri-
ologically confirmed cases [25]. The high yield highlights the 
importance of active case-finding strategies such as HHCT. 
These findings also emphasize the need for scaling-up TB pre-
ventive therapies to such high-risk groups, a strategy that has 
been shown to be highly effective among contacts exposed to 
infectious TB cases [26].
Our findings on Xpert performance contrast with a recent 
study conducted by Lebina et  al [27] among HHCs, which 
found no significant difference in diagnostic yield between 
Xpert and culture. It is possible that differences in our study 
sample preparation and testing, ie, both culture and Xpert tests 
were conducted from 1 sample in our study, which differed 
from the Lebina et al [27] study, which used 2 separate samples 
for comparison, might explain the contrasting results. The sen-
sitivity of Xpert varies in different settings, ranging from 58% to 
100% [28]; however, there are few estimates of its performance 
for HHCT. One study from Tanzania reported a sensitivity of 
100% among 5 culture-positive contacts, whereas another from 
the Gambia among 14 culture-positive children <15 years re-
ported a sensitivity of 42.9% [18, 19]. We found no difference in 
sensitivity and specificity of Xpert by HIV status and a higher 
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the limited evidence of Xpert performance in real-world con-
ditions and our contrasting findings, national TB programs 
should consider selection of TB testing strategies based on their 
own operational research.
The poor sensitivity of Xpert from our study and previous 
studies [18, 19] have been explained by lower sputum bacillary 
burden present during early development of TB disease, dem-
onstrated among HHCs or children [29]. A  study that diag-
nosed TB in children <15 years old within a primary healthcare 
setting, reported an Xpert sensitivity of 43.3% when compared 
with culture [30]. Further evidence supporting a link to bac-
illary burden and reduced Xpert sensitivity can be found in 
TTCP; where there is a low sputum bacillary burden, TTCP 
is usually longer, which correlates with poorer sensitivity of 
Xpert [23, 31]. Our results show a similar trend; among culture-
positive TB patients, median TTCP was shorter in Xpert-
positive patients compared with Xpert-negative patients (6 vs 
17 days), lending credibility to poorer Xpert sensitivity due to 
lower bacillary burden.
Our findings have important implications for Xpert use 
among HHCs, implying that in the absence of culture testing, 
substantial TB cases would have been missed, and therefore lim-
iting the impact of contact tracing for TB control. The need for 
an improved diagnostic test among HHCs is compounded by 
high resources required for contact tracing [8, 32]; use of Xpert 
among HHCs would be an inefficiency of resources if only one 
fifth of cases are being identified according to our study. In our 
study, Xpert was also positive on an additional 9 patients; 4 were 
culture-negative and included in this analysis and 5 that were 
culture-contaminated and not included. Among the 4 Xpert-
positive, culture-negative patients, 2 were smear-negative and 
2 were-smear positive; the smear-negative TB patients also re-
ported previous TB, which might explain the Xpert-positive re-
sult as a possible false-positive. However, the 2 smear-positive 
patients might be indicative of a false-negative culture result. 
Xpert-positive, culture-negative results have been reported 
elsewhere [33], and such results underscore the difficulties with 
Xpert interpretation. Additional long-term follow-up studies 
are required to understand their clinical outcomes [16].
Xpert yield in our study was higher than smear microscopy 
(2.6% vs 1.0%, respectively), a trend that is consistent with other 
studies [14, 18, 29, 32], and, more importantly, it did identify all 
smear-positive cases (3 of 3). Smear microscopy remains a main-
stay of TB testing in many countries [29]; however, our findings 
emphasize the need for an alternate testing method. The exten-
sive rollout of Xpert globally will likely replace smear microscopy 
as the initial TB test; however, given its poor diagnostic perfor-
mance among presumptive TB contacts, further consideration 
should be given to identifying a suitable testing algorithm, espe-
cially the Xpert-negative pathway after initial testing. Although 
our study highlighted the poor diagnostic performance of Xpert 
compared with culture, its ease of implementation does counter its 
shortcomings for diagnosing TB. In particular, Xpert requires lim-
ited laboratory infrastructure and human resources, has a quicker 
turnaround for results, and minimizes the possibility of sample 
contamination, all of which are limitations associated with culture 
testing. Thus, microbiological testing among contacts may require 
a solution that balances the need for quicker results, minimal labo-
ratory infrastructure, and costs but limits missed diagnoses. An al-
gorithm that combines Xpert and culture testing may be possible, 
a strategy that has shown to improve yield [18].
We found no difference in the sensitivity and specificity of 
Xpert by HIV status, albeit with very low statistical power, con-
sistent with a study from Tanzania where Xpert performance 
was not affected by HIV status [34]. Contradictory evidence 
suggests that the impact of HIV status on Xpert sensitivity 
decreased when adjusting for percentage smear-positive, sug-
gesting that differences may be attributed to differences in 
smear status [28, 35]. In the context of HHCT, this issue maybe 
be important for countries with high HIV prevalence who opt 
for the exclusive use of Xpert; recent evidence evaluating the 
use of GeneXpert MTB/RIF Ultra among HIV-positive patients 
suggests that some of these trade-offs might be overcome [16]. 
Our study results affirm the importance of TB screening and 
testing of all HHCs to rule out TB disease regardless of HIV 
status; specifically, this will remove an important barrier to ini-
tiation and scale-up of TB preventive therapy.
The study has several strengths that make the findings rel-
evant to national TB programs. First, this is one of the lar-
gest studies to evaluate Xpert performance for diagnosing TB 
among HHCs in “real-world” conditions. Second, we tested 
almost all HHCs investigated with smear microscopy, culture, 
and Xpert, making it appropriate to compare the yield and 
sensitivities. Third, laboratory testing was conducted by 1 lab-
oratory to clinical trial standards. However, there are several 
limitations to our study. First, our small numbers of contacts 
and culture-confirmed TB cases limits the precision of our esti-
mates. Second, we only requested a single spot sputum, and the 
quantity and quality of sample may have affected the yield of 
TB; however, our study showed a higher yield of TB compared 
with other studies. Third, using a single spot sputum for cul-
ture may have resulted in a lower Xpert PPV estimate because 
5 samples that were positive on Xpert were contaminated on 
culture and excluded from the analysis.
CONCLUSIONS
Xpert may allow for a shorter time to diagnosis compared with 
mycobacterial culture as well as simultaneous detection of 
RR-TB [14]; however, its performance against culture in our 
study has been suboptimal. The Xpert Ultra assay, developed 
to overcome many inherent limitations of the original Xpert 
assay [16] with its lower limit of detection, has been touted to 
offer improved sensitivity for detecting TB. Among sympto-
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of the smear-negative culture-positive TB cases. The poor 
performance of Xpert for diagnosing TB among symptomatic 
HHCs suggests that consideration to a more sensitive test such 
a Xpert Ultra, in combination with mycobacterial culture, may 
be needed to optimize contact investigation.
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